Ipamorelin

Growth HormonePHASE 2

Clinical Status

Investigational — Phase II trials discontinued.

Mechanism of Action

Binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH.

Dosing Defaults

Dose

200-300 mcg

Frequency

2-3x daily

Administration

Subcutaneous injection

Timing

Before bed or morning (fasted)

Food

fasted

Duration

8-12 weeks

Dose range: 100-500 mcg per dose

GH secretagogues work best fasted — food blunts GH release. Evening dosing aligns with natural GH pulses during sleep.

Side Effects

•Injection site reactions
•Headache
•Nausea
•Increased appetite
•Water retention
•Joint stiffness (temporary)

Contraindications & Warnings

⚠Active malignancy

•Not medical advice

Compare

Compare Ipamorelin with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Ipamorelin dose.

Open Calculator

Related Growth Hormone Peptides

CJC-1295

PHASE 2

Growth Hormone

Synthetic GHRH analog that stimulates GH release from the pituitary.

CJC-1295 DAC

PHASE 2

Growth Hormone

Long-acting version of CJC-1295 with extended half-life via albumin binding.

Tesamorelin

FDA APPROVED

Growth Hormone

FDA-approved GHRH analog for visceral fat reduction in HIV lipodystrophy.

Sermorelin

FDA APPROVED

Growth Hormone

Truncated GHRH analog. Previously FDA-approved for pediatric GH deficiency.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.